COMPASS PATHWAYS PLC Financing Cash Flow
COMPASS PATHWAYS PLC (CMPS) reported Financing Cash Flow of $370.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $7.56M, a 4453.61% increase year-over-year.
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $362.45M, a 158.23% increase year-over-year.
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $187.00K, a 20.65% increase year-over-year.
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for fiscal 2025 was $140.71M, a 120.47% increase from fiscal 2024.
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for fiscal 2024 was $63.82M, a 63.28% decline from fiscal 2023.
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for fiscal 2023 was $173.83M, a 16614.42% increase from fiscal 2022.
- COMPASS PATHWAYS PLC net cash provided by (used in) financing activities for fiscal 2022 was $1.04M, a 99.34% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $370.01M 10-Q · filed 2026-08-05 | $370.20M derived: sum of 3 quarters · filed 2026-08-05 | $370.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $362.45M 10-Q · filed 2026-05-13 | $362.64M derived: sum of 2 quarters · filed 2026-05-13 | $362.64M derived: sum of 3 quarters · filed 2026-05-13 | $362.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $187.00K derived: sum of 2 quarters · filed 2026-03-24 | $353.00K derived: sum of 3 quarters · filed 2026-08-05 | $140.71M 10-K · filed 2026-03-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $166.00K derived: sum of 2 quarters · filed 2026-08-05 | $140.53M 10-Q · filed 2025-11-04 | $140.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $140.53M 10-Q · filed 2026-08-05 | $140.68M derived: sum of 3 quarters · filed 2026-08-05 | $140.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $140.36M 10-Q · filed 2026-05-13 | $140.51M derived: sum of 2 quarters · filed 2026-05-13 | $140.46M derived: sum of 3 quarters · filed 2026-05-13 | $140.67M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $102.00K derived: sum of 2 quarters · filed 2026-03-24 | $312.00K derived: sum of 3 quarters · filed 2026-03-24 | $63.82M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $157.00K derived: sum of 2 quarters · filed 2025-11-04 | $63.67M 10-Q · filed 2025-11-04 | $63.71M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $63.72M 10-Q · filed 2025-07-31 | $63.76M derived: sum of 3 quarters · filed 2025-07-31 | $180.54M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $63.51M 10-Q · filed 2025-05-08 | $63.55M derived: sum of 2 quarters · filed 2025-05-08 | $180.33M derived: sum of 3 quarters · filed 2025-05-08 | $236.26M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $116.82M derived: sum of 2 quarters · filed 2025-02-27 | $172.75M derived: sum of 3 quarters · filed 2025-02-27 | $173.83M 10-K · filed 2025-02-27 |
| 2023-09-30 | $116.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $172.71M derived: sum of 2 quarters · filed 2024-10-31 | $173.79M 10-Q · filed 2024-10-31 | $174.43M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $55.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $57.01M 10-Q · filed 2024-08-01 | $57.65M derived: sum of 3 quarters · filed 2024-08-01 | $57.65M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $1.08M 10-Q · filed 2024-05-08 | $1.72M derived: sum of 2 quarters · filed 2024-05-08 | $1.72M derived: sum of 3 quarters · filed 2024-05-08 | $1.93M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $639.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $638.00K derived: sum of 2 quarters · filed 2024-02-29 | $851.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.04M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $212.00K derived: sum of 2 quarters · filed 2023-11-02 | $401.00K 10-Q · filed 2023-11-02 | $1.21M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $402.00K 10-Q · filed 2023-08-03 | $1.21M derived: sum of 3 quarters · filed 2024-02-29 | $1.26M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $189.00K 10-Q · filed 2023-05-11 | $994.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.04M derived: sum of 3 quarters · filed 2024-02-29 | $155.88M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $805.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $854.00K derived: sum of 2 quarters · filed 2024-02-29 | $155.69M derived: sum of 3 quarters · filed 2024-02-29 | $156.65M 10-K · filed 2024-02-29 |
| 2021-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $154.88M derived: sum of 2 quarters · filed 2022-11-03 | $155.84M 10-Q · filed 2022-11-03 | $155.86M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $154.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $155.79M 10-Q · filed 2022-08-04 | $155.81M derived: sum of 3 quarters · filed 2023-02-28 | $294.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $958.00K 10-Q · filed 2022-05-10 | $974.00K derived: sum of 2 quarters · filed 2023-02-28 | $139.23M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $16.00K derived: 10-K 12 month − 6-K 9 month · filed 2023-02-28 | $138.27M derived: sum of 2 quarters · filed 2023-02-28 | $194.16M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $138.25M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-09 | $194.14M 6-K · filed 2021-11-09 | ||
| 2020-06-30 | $55.89M 6-K · filed 2021-08-11 | |||
| 2019-12-31 | $18.38M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |